Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KeyPARTNER
2023-507008-30-00Phase 2Authorised
- Sponsor
- Champalimaud Clinical Centre
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of pembrolizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Champalimaud Clinical Centre. Primary endpoints: Pathological complete response (pCR) and Fate bifurcation of tumor infiltrating lymphocytes. Planned start Mar 2024; status: authorised.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-507008-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507008-30-00.